Program areas at CARE
Mayo Clinic in AZ - Funding two Mayo Clinic projects: 1) Predicting Metastatic Potential Cutaneous Squamous Cell Carcinoma, and 2) Targeting Metastatic Prostate Cancer With Novel Fn14Predicting Metatasic Potential Cutaneous Squamous Cell Carcinoma Using Gene Expression Profiling:Cutaneous squamous cell carcinoma (cSCC) affects more than one million individuals annually in the United States. Its incidence is rising due to ultraviolet exposure and an increase in the population of elderly and immunosuppressed individuals. Most cSCC is curable by surgery, but metastasis occurs in up to 5% of patients. Metastatic cSCC carries a poor five-year survival (25-35%) and accounts for nearly 8,800 deaths annually, comparable to the mortality rate of malignant melanoma.There is a great need for more accurate identification of tumors with metastatic potential to truly characterize cSCC patients that are at high risk. Mayo Clinics research team has developed a method based on gene expression profiling (GEP) that can stratify intermediate to high-risk cSCC for overall survival by 20-fold and can properly stratify 95% of intermediate to high-risk tumors as non-metastatic and 70% of intermediate to high-risk tumors as metastatic. Validation of this panel would permit design of not only a new test, but an entire new way of assessing the risk in one of the most common human cancers, SCC.Targeting Metastatic Prostate Cancer With Novel Fn14 Inhibitory Compound:Prostate cancer (PCa) is the second leading cause of cancer related death in American men. Like normal prostate tissue, which requires androgen hormones produced by the body to function, so do prostate cancer cells. Thus, treatment for PCa frequently involves either reducing the supply of androgens by blocking androgen synthesis in the body or disrupting the stimulation of cancer cells through blockade of androgen receptor signals in cancer cells. This approach is known as androgen deprivation therapy (ADT). Although initial response rates are promising, all men eventually progress on ADT and develop a resistant version of prostate cancer, which undergoes metastatic spread. At this metastatic stage, specifically when metastasized to the bone, PCa is incurable, and an increasing number of men are developing a highly lethal variant of PCa known as aggressive variant prostate cancer (AVPC). Androgen receptor signaling is lost in AVPC rendering the existing hormone targeting treatments ineffective. To date, very few therapies exist for AVPC and only offer minimal survival benefits in this setting. Thus, the identification and assessment of drug targeting VAPC are needed to effectively treat and control metastasis.
HonorHealth Research Institute - Funding two HHRI projects: 1) Uveal Melanoma Study, and 2) Tenosynovial Giant Cell Tumor StudyUveal Melanoma:Uveal melanoma (UM) is a rare subtype that arises typically in the choroidal body of the eye. Unlike cutaneous (skin) melanoma, UM has been resistant to current immunotherapy and at the present time, there is no FDA approved treatment for this disease making it both a rare and refractory disease. HHRIs goal is to identify novel biomarkers for disease monitoring and diagnosis with the expectation that such biomarkers can be used to identify patients at highest risk for recurrence and utilize these biomarkers as a surrogate endpoint in the adjuvant setting.Tenosynovial Giant Cell Tumor: Tenosynovial giant cell tumor (TGCT) is a rare sarcomatous proliferation of the synovium lining the joints. This disorder typically occurs in young men and women and most often impact the large joints, particularly the knees.By the time patients present for diagnosis, the TGCT proliferation if most often not completely resectable and surgery has limited value. MRI scans have classical features for this diagnosis but suffer from inaccuracy and the fact that a tissue diagnosis is needed to move forward with systemic therapy. Treatment for TGCT includes the orally administered targeted drug pexidartinib which can be associated with the development of liver failure making its use somewhat complex. The lack of a simple diagnostic test, as opposed to having to proceed with surgery and biopsy, places patients at greater risk for complications. We have identified this as a potentially game-changing opportunity since most of these patients present not only with the synovial proliferation but also with a detectable joint effusion (fluid) that can be aspirated. HHRI is proposing to subject new diagnosed and untreated patients to a joint effusion aspiration as well as the necessary surgical biopsy (if not already performed) to develop an effusion-driven biomarker analysis allowing an alternate mechanism for securing the diagnosis of TGCT
Who funds Cancer Awareness Through Research and Education (CARE)
Grants from foundations and other nonprofits
Personnel at CARE
Name | Title | Compensation | Date of data |
---|
J Derek Hill | Treasurer | $0 | 2023-03-20 |
Suzanne Paetzer | Vice Chair and Secretary | $0 | 2022-06-30 |
Jill Porcellato | Chairman | $0 | 2022-06-30 |
Louise Zirretta | Vice Chair | $0 | 2020-09-30 |
Sandra Miller-Forman | Treasurerand Board Member | $0 | 2019-09-30 |
...and 3 more key personnel |
Financials for CARE
Revenues | FYE 06/2022 | FYE 09/2021 | % Change |
---|
Total grants, contributions, etc. | $1,085,260 | $563,708 | 92.5% |
Program services | $0 | $5,463 | -100% |
Investment income and dividends | $28 | $20 | 40% |
Tax-exempt bond proceeds | $0 | $0 | - |
Royalty revenue | $0 | $0 | - |
Net rental income | $0 | $0 | - |
Net gain from sale of non-inventory assets | $-183 | $52 | -451.9% |
Net income from fundraising events | $-165,665 | $-70,417 | -135.3% |
Net income from gaming activities | $49,695 | $39,500 | 25.8% |
Net income from sales of inventory | $0 | $0 | - |
Miscellaneous revenues | $0 | $0 | - |
Total revenues | $969,135 | $538,326 | 80% |
Organizations like CARE
Organization | Type | Location | Revenue |
---|
Stanley M Marks Blood Cancer Research Fund | 501(c)(3) | Pittsburgh, PA | $685,456 |
Tower Cancer Research Foundation (TCRF) | 501(c)(3) | Beverly Hills, CA | $2,998,998 |
Cancer League of Colorado | 501(c)(3) | Englewood, CO | $1,684,307 |
Hirshberg Foundation for Pancreatic Cancer Research | 501(c)(3) | Los Angeles, CA | $2,209,480 |
Carol M Baldwin Breast Cancer Research Fund of Central New York | 501(c)(3) | Warners, NY | $419,664 |
Sarcoma Foundation of America | 501(c)(3) | Damascus, MD | $3,973,362 |
Inc Nutrition Research and Education Foundation | 501(c)(3) | Winters, CA | $425,971 |
Pap Corps Champions for Cancer Research | 501(c)(3) | Deerfield Beach, FL | $4,091,116 |
Womens Cancer Research Foundation | 501(c)(3) | Laguna Beach, CA | $685,705 |
American-Italian Cancer Foundation (AICF) | 501(c)(3) | New York, NY | $1,660,961 |
Data update history
June 17, 2023
Posted financials
Added Form 990 for fiscal year 2022
June 15, 2023
Updated personnel
Identified 2 new personnel
May 14, 2023
Used new vendors
Identified 2 new vendors, including , and
April 14, 2022
Updated personnel
Identified 1 new personnel
Nonprofit Types
Grantmaking organizationsDisease research fundraisersMedical research organizationsCharities
Issues
HealthEducationDiseases and disordersCancer
Characteristics
Provides grantsConducts researchFundraising eventsGala fundraisersAuction fundraisersFundraising races, competitions, and tournamentsTax deductible donationsNo full-time employees
General information
- Address
- PO Box 3740
- Carefree, AZ 85377
- Metro area
- Phoenix-Mesa-Chandler, AZ
- County
- Maricopa County, AZ
- Website URL
- caredm.org/Â
- Phone
- (952) 221-7432
IRS details
- EIN
- 20-3771288
- Fiscal year end
- September
- Taxreturn type
- Form 990
- Year formed
- 2005
- Eligible to receive tax-deductible contributions (Pub 78)
- Yes
Categorization
- NTEE code, primary
- H30: Cancer Research
- NAICS code, primary
- 813212: Health and Disease Research Fundraising Organizations
- Parent/child status
- Independent
Free account sign-up
Want updates when CARE has new information, or want to find more organizations like Cancer Awareness Through Research and Education (CARE)?
Create free Cause IQ account